View all trials
Are you a member? Sign in above to view additional information
  • Study title
    A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND#58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC#724772) for Patients with High Allelic Ratio FLT3/ITD
  • Protocol ID
    AAML1031
  • Disease
    Disease Type Disease Subtype
    Leukaemia
    AML
  • Eligibility criteria
  • Study Status
    Open
  • Location(s)
    Children's Hospital at Westmead
    • Centre Study Status:
      Open
    • Notes:
    Lady Cilento Children's Hospital
    • Centre Study Status:
      Open
    • Notes:
    Princess Margaret Hospital
    • Centre Study Status:
      Open
    • Notes:
    Royal Children's Hospital Melbourne
    • Centre Study Status:
      Open
    • Notes:
    Sydney Children's Hospital
    • Centre Study Status:
      Open
    • Notes:
  • Phase
    Phase 2/3
  • Study type
    Treatment
  • Diagnosis stage
    New diagnosis
  • Study open date
    20/06/2011
  • Study close date
    N/A
  • Study chair
    Dr Richard Aplenc
  • Sponsor
    Children's Oncology Group
Back to search results